FDA Approves Sandoz Biosimilar for Tysabri® | McDonnell Boehnen Hulbert & Berghoff LLP
It was not so long ago that many, including members of Congress, were bemoaning the slow approval and introduction into the marketplace of biosimilar alternatives to (generally...
Drug Administration Plan For Further Facilitating Biosimilar Development Administration Considering Reduction Biologics Exclusivity Further Facilitating Biosimilar Investigate Biosimilar Litigation Settlement
Source: jdsupra.com